1449117-31-0 Usage
General Description
2,4-dichloro-6-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyriMidine is a chemical compound with a complex molecular structure. It contains two chlorine atoms and a cyclopropyl group, as well as a tetrahydropyrido[4,3-d]pyridine ring system. 2,4-dichloro-6-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyriMidine has potential applications in the field of medicinal chemistry, particularly as a candidate for drug development. Its unique structure and potential biological activity make it an interesting target for further research and investigation. However, due to its complex nature, it may also pose challenges in terms of synthesis and handling.
Check Digit Verification of cas no
The CAS Registry Mumber 1449117-31-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,9,1,1 and 7 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1449117-31:
(9*1)+(8*4)+(7*4)+(6*9)+(5*1)+(4*1)+(3*7)+(2*3)+(1*1)=160
160 % 10 = 0
So 1449117-31-0 is a valid CAS Registry Number.
1449117-31-0Relevant articles and documents
Discovery and Optimization of Glucose Uptake Inhibitors
Liu, Kevin G.,Kim, Ji-In,Olszewski, Kellen,Barsotti, Anthony M.,Morris, Koi,Lamarque, Christophe,Yu, Xuemei,Gaffney, Jack,Feng, Xiao-Jiang,Patel, Jeegar P.,Poyurovsky, Masha V.
supporting information, p. 5201 - 5211 (2020/07/10)
Aerobic glycolysis, originally identified by Warburg as a hallmark of cancer, has recently been implicated in immune cell activation and growth. Glucose, the starting material for glycolysis, is transported through the cellular membrane by a family of glucose transporters (GLUTs). Therefore, targeting glucose transporters to regulate aerobic glycolysis is an attractive approach to identify potential therapeutic agents for cancers and autoimmune diseases. Herein, we describe the discovery and optimization of a class of potent, orally bioavailable inhibitors of glucose transporters, targeting both GLUT1 and GLUT3.
